Table 1.
Characteristics of study participants at baseline (N=930).
| Characteristics | Control group (n=468) | Intervention group (n=462) | Participants (N=930) | ||||
| Age (years), mean (SD) | 63.1 (10) | 64.0 (9.7) | 63.5 (9.8) | ||||
| Gender, n (%) | |||||||
|
|
Female | 92 (19.7) | 109 (23.6) | 201 (21.6) | |||
|
|
Male | 376 (80.3) | 353 (76.4) | 729 (78.4) | |||
| Time since the last event, n (%) | |||||||
|
|
Less than 3 months | 62 (13.3) | 43 (9.3) | 105 (11.3) | |||
|
|
3 to 12 months | 84 (17.9) | 97 (21) | 181 (19.5) | |||
|
|
1 to 3 years | 144 (30.8) | 122 (26.4) | 266 (28.6) | |||
|
|
More than 3 years | 178 (38) | 200 (43.3) | 378 (40.7) | |||
| Type event, n (%) | |||||||
|
|
Acute coronary syndrome | 336 (71.8) | 327 (70.8) | 663 (71.3) | |||
|
|
Stable angina | 33 (7.1) | 23 (5) | 56 (6) | |||
|
|
Ischemic cerebrovascular disease | 21 (4.5) | 21 (4.6) | 42 (4.5) | |||
|
|
Peripheral arterial disease | 15 (3.2) | 21 (4.6) | 36 (3.9) | |||
|
|
Coronary revascularization | 63 (13.5) | 70 (15.2) | 133 (14.3) | |||
| Prescribed medications, n (%) | |||||||
|
|
Statins | 414 (88.5) | 413 (89.4) | 827 (88.9) | |||
|
|
ACEIa or ARBsb | 327 (69.9) | 306 (66.2) | 633 (68.1) | |||
|
|
β-blocker | 382 (81.6) | 392 (84.9) | 774 (83.2) | |||
|
|
Platelet aggregation inhibitors | 442 (94.4) | 437 (94.6) | 879 (94.5) | |||
| MARS-5c score, mean (SD) | 22.8 (3.78) | 23 (3.31) | 22.9 (3.6) | ||||
| Adherent (MARS-5 score=25 points), n (%) | 199 (42.5) | 189 (40.9) | 388 (41.7) | ||||
| Self-reported adherence, mean (SD) | |||||||
|
|
Last 7 days (0-10 scale) | 9.1 (2.04) | 9.1 (2.19) | 9.1 (2.1) | |||
|
|
30 days (0-10 scale) | 9.1 (1.95) | 9.1 (2.05) | 9.1 (2) | |||
| PHQ-9d, n (%) | |||||||
|
|
Minimal depression (<5) | 343 (73.3) | 323 (69.9) | 666 (71.6) | |||
|
|
Moderate depression (5-14) | 112 (24) | 127 (27.5) | 239 (25.7) | |||
|
|
Moderately severe depression or severe (>14) | 12 (2.6) | 13 (2.8) | 25 (2.7) | |||
| Smoking, n (%) | |||||||
|
|
Smoker | 16 (3.4) | 12 (2.6) | 28 (3) | |||
|
|
Never smoked | 168 (35.9) | 185 (40) | 353 (38) | |||
|
|
Past smoker | 284 (60.7) | 265 (57.4) | 549 (59) | |||
| BMI (m/kg2), mean (SD) | 27.9 (4.2) | 27.3 (4.2) | 27.6 (4.2) | ||||
| LDLe (mg/dl), mean (SD) | 88.2 (37.4) | 88.5 (38.0) | 88.4 (37.7) | ||||
| SBPf (mmHg), mean (SD) | 128.2 (20.8) | 129.9 (20.9) | 129.0 (20.9) | ||||
| DBPg (mmHg), mean (SD) | 71.5 (11.7) | 71.9 (11.3) | 71.7 (11.5) | ||||
| Heart rate (bpm), mean (SD) | 68.9 (11.7) | 68.8 (10.6) | 68.8 (11.1) | ||||
| Thromboxane B2h (ng/ml), mean (SD) | 64.1 (147.2) | 64.2 (167.7) | 64.2 (157.6) | ||||
aACEI: angiotensin-converting enzyme inhibitor.
bARB: angiotensin II receptor blocker.
cMARS-5: Medication Adherence Report Scale-5.
dPHQ-9: Patient Health Questionnaire-9.
eLDL: low-density lipoprotein.
fSBP: systolic blood pressure.
gDBP: diastolic blood pressure.
hCreatinine adjusted (mg/dl).